CI
Clal Insurance’s Vertex Pharmaceuticals VRTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.12M | Buy |
2,520
+2,465
| +4,482% | +$1.1M | 0.01% | 95 |
|
|
2025
Q1 | $27K | Buy |
55
+45
| +450% | +$22.1K | ﹤0.01% | 136 |
|
|
2024
Q4 | $4K | Buy |
+10
| New | +$4K | ﹤0.01% | 153 |
|
|
2023
Q1 | – | Sell |
-165,240
| Closed | -$47.7M | – | 150 |
|
|
2022
Q4 | $47.7M | Sell |
165,240
-47,000
| -22% | -$13.6M | 0.72% | 44 |
|
|
2022
Q3 | $61.5M | Sell |
212,240
-5,000
| -2% | -$1.45M | 0.84% | 37 |
|
|
2022
Q2 | $61.2M | Sell |
217,240
-47,760
| -18% | -$13.5M | 0.81% | 41 |
|
|
2022
Q1 | $69.2M | Sell |
265,000
-216,000
| -45% | -$56.4M | 0.73% | 42 |
|
|
2021
Q4 | $106M | Buy |
481,000
+323,500
| +205% | +$71M | 1.14% | 25 |
|
|
2021
Q3 | $28.6M | Buy |
157,500
+153,000
| +3,400% | +$27.8M | 0.33% | 85 |
|
|
2021
Q2 | $907K | Buy |
+4,500
| New | +$907K | 0.01% | 151 |
|